Recently, it was demonstrated that immunosuppression-naïve, JCV Ab + NTZ-treated MS patients with a low anti-JCV Ab index carry a several-fold lower PML risk than those with a high index, and the quantification of anti-JCV Ab levels was suggested to improve PML risk stratification [16,17]. This evidence concerns the gene PML and myeloid sarcoma.